ResMed (NYSE:RMD) Given New $277.00 Price Target at KeyCorp

ResMed (NYSE:RMD) had its price objective increased by equities research analysts at KeyCorp from $267.00 to $277.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has an “overweight” rating on the medical equipment provider’s stock. KeyCorp‘s price target points to a potential upside of 9.92% from the stock’s current price.

A number of other research firms also recently issued reports on RMD. Jefferies Financial Group cut their price target on ResMed from $240.00 to $225.00 and set a “hold” rating for the company in a research note on Friday, July 10th. Piper Sandler decreased their price target on shares of ResMed from $233.00 to $225.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Mizuho set a $270.00 price target on shares of ResMed in a report on Friday. Royal Bank Of Canada upgraded shares of ResMed from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $244.00 to $262.00 in a research note on Tuesday, September 15th. Finally, Citigroup reaffirmed a “neutral” rating on shares of ResMed in a report on Thursday, September 10th. Seven investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $246.31.

ResMed Stock Performance

Shares of NYSE:RMD opened at $252.00 on Friday. ResMed has a fifty-two week low of $180.26 and a fifty-two week high of $277.67. The firm’s 50 day simple moving average is $231.83 and its 200 day simple moving average is $225.57. The company has a market capitalization of $35.44 billion, a price-to-earnings ratio of 24.16, a P/E/G ratio of 1.53 and a beta of 0.75. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.10 and a quick ratio of 2.42.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $0.24. The firm had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.39 billion. ResMed had a net margin of 26.94% and a return on equity of 25.58%. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.55 EPS. As a group, sell-side analysts forecast that ResMed will post 12.11 earnings per share for the current year.

Insider Buying and Selling at ResMed

In other ResMed news, CEO Michael Farrell sold 4,991 shares of the company’s stock in a transaction dated Wednesday, October 7th. The shares were sold at an average price of $226.33, for a total value of $1,129,613.03. Following the transaction, the chief executive officer directly owned 479,803 shares in the company, valued at $108,593,812.99. This represents a 1.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter Farrell sold 970 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $234.73, for a total value of $227,688.10. Following the completion of the sale, the director owned 51,803 shares in the company, valued at approximately $12,159,718.19. This represents a 1.84% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 24,343 shares of company stock valued at $5,396,098 over the last ninety days. 0.58% of the stock is currently owned by company insiders.

Institutional Trading of ResMed

A number of institutional investors have recently bought and sold shares of RMD. Bell Investment Advisors Inc purchased a new position in shares of ResMed in the second quarter valued at $26,000. Trust Co. of Vermont acquired a new position in ResMed in the 2nd quarter worth $39,000. Kelleher Financial Advisors acquired a new stake in shares of ResMed during the second quarter valued at about $47,000. Harbor Investment Advisory LLC grew its stake in shares of ResMed by 82.6% during the second quarter. Harbor Investment Advisory LLC now owns 409 shares of the medical equipment provider’s stock valued at $80,000 after acquiring an additional 185 shares in the last quarter. Finally, Ballast Advisors LLC purchased a new stake in shares of ResMed during the first quarter worth about $84,000. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q1 earnings and revenue beat estimates. ResMed reported fiscal Q1 2027 adjusted earnings of $2.91 per share, above the $2.67 analyst consensus and up from $2.55 a year earlier. Revenue rose 5.9% year over year to $1.41 billion, exceeding the $1.39 billion estimate. The company also reported a 26.94% net margin and 25.58% return on equity, reinforcing the earnings-driven support for RMD. ResMed Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Dividend maintained at $0.66 per share. ResMed declared a quarterly dividend payable December 17 to shareholders of record November 12. The $2.64 annualized payout represents an approximately 1.0% yield and adds to shareholder returns, although the ex-dividend date may produce normal short-term trading adjustments. ResMed Posts Strong Q1 Results and Shareholder Returns
• Neutral Sentiment: Investors will focus on the outlook and valuation. Earnings-call coverage highlighted the quarterly performance, while ResMed’s shares trade near the upper end of their 52-week range. With a reported price-to-earnings ratio of about 24, continued appreciation may depend on sustaining growth beyond the current 6% revenue expansion. ResMed Q1 2027 Earnings Call Transcript

About ResMed

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.